Xiaoping Bao

Xiaoping Bao

Auto-generated profile, based on publicly available information

Xiaoping Bao

Davidson School of Chemical Engineering Purdue University West Lafayette Indiana USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2012 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
XLXiaojun Lian
Xiaojun Lian
JZJianhua Zhang
Jianhua Zhang
SASamira M Azarin
Samira M Azarin
KZKexian Zhu
Kexian Zhu
LHLaurie B Hazeltine
Laurie B Hazeltine
SPSean Palecek
Sean Palecek

1 November 2014 in Stem Cell Reports
Verified
Journal Article
Open access
XLXiaojun Lian
Xiaojun Lian
XBXiaoping Bao
Xiaoping Bao
AAAbraham Al-Ahmad
Abraham Al-Ahmad
JLJialu Liu
Jialu Liu
YWYue Wu
Yue Wu
SPSean Palecek
Sean Palecek
Human pluripotent stem cell (hPSC)-derived endothelial cells and their progenitors may provide the means for vascularization of tissue-engineered constructs and can serve as models to study vascular development and disease. Here, we report a method to efficiently produce endothelial cells from hPSCs via GSK3 inhibition and culture in defined media to direct hPSC differentiation to CD34(+)CD31(+) endothelial progenitors. Exogenous vascular endothelial growth factor (VEGF) treatment was dispensable, and endothelial progenitor differentiation was β-catenin dependent. Furthermore, by clonal analysis, we showed that CD34(+)CD31(+)CD117(+)TIE-2(+) endothelial progenitors were multipotent, capable of differentiating into calponin-expressing smooth muscle cells and CD31(+)CD144(+)vWF(+)I-CAM1(+) endothelial cells. These endothelial cells were capable of 20 population doublings, formed tube-like structures, imported acetylated low-density lipoprotein, and maintained a dynamic barrier function. This study provides a rapid and efficient method for production of hPSC-derived endothelial progenitors and endothelial cells and identifies WNT/β-catenin signaling as a primary regulator for generating vascular cells from hPSCs.

3 November 2017 in Science Advances
Verified
Journal Article
Open access
PDF file
TQTongcheng Qian
Tongcheng Qian
SMShaenah E. Maguire
Shaenah E. Maguire
SCScott Canfield
Scott Canfield
XBXiaoping Bao
Xiaoping Bao
WOWilliam R. Olson
William R. Olson
SPSean Palecek
Sean Palecek
The blood-brain barrier (BBB) is composed of specialized endothelial cells that are critical to neurological health. A key tool for understanding human BBB development and its role in neurological disease is a reliable and scalable source of functional brain microvascular endothelial cells (BMECs). Human pluripotent stem cells (hPSCs) can theoretically generate unlimited quantities of any cell lineage in vitro, including BMECs, for disease modeling, drug screening, and cell-based therapies. We demonstrate a facile, chemically defined method to differentiate hPSCs to BMECs in a developmentally relevant progression via small-molecule activation of key signaling pathways. hPSCs are first induced to mesoderm commitment by activating canonical Wnt signaling. Next, these mesoderm precursors progress to endothelial progenitors, and treatment with retinoic acid leads to acquisition of BBB-specific markers and phenotypes. hPSC-derived BMECs generated via this protocol exhibit endothelial properties, including tube formation and low-density lipoprotein uptake, as well as efflux transporter activities characteristic of BMECs. Notably, these cells exhibit high transendothelial electrical resistance above 3000 ohm·cm2. These hPSC-derived BMECs serve as a robust human in vitro BBB model that can be used to study brain disease and inform therapeutic development.

20 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYun Chang
Yun Chang
XCXuechao Cai
Xuechao Cai
RSRamizah Syahirah
Ramizah Syahirah
YYYuxing Yao
Yuxing Yao
YXYang Xu
Yang Xu
XBXiaoping Bao
Xiaoping Bao
Glioblastoma (GBM) is one of the most aggressive and lethal solid tumors in human. While efficacious therapeutics, such as emerging chimeric antigen receptor (CAR)-T cells and chemotherapeutics, have been developed to treat various cancers, their effectiveness in GBM treatment has been hindered largely by the blood-brain barrier and blood-brain-tumor barriers. Human neutrophils effectively cross physiological barriers and display effector immunity against pathogens but the short lifespan and resistance to genome editing of primary neutrophils have limited their broad application in immunotherapy. Here we genetically engineer human pluripotent stem cells with CRISPR/Cas9-mediated gene knock-in to express various anti-GBM CAR constructs with T-specific CD3ζ or neutrophil-specific γ-signaling domains. CAR-neutrophils with the best anti-tumor activity are produced to specifically and noninvasively deliver and release tumor microenvironment-responsive nanodrugs to target GBM without the need to induce additional inflammation at the tumor sites. This combinatory chemo-immunotherapy exhibits superior and specific anti-GBM activities, reduces off-target drug delivery and prolongs lifespan in female tumor-bearing mice. Together, this biomimetic CAR-neutrophil drug delivery system is a safe, potent and versatile platform for treating GBM and possibly other devastating diseases.

30 June 2015 in Nature Methods
Verified
Journal Article
Closed access
PDF file
XLXiaojun Lian
Xiaojun Lian
XBXiaoping Bao
Xiaoping Bao
MZMisha Zilberter
Misha Zilberter
MWMattias Westman
Mattias Westman
AFAndré Fisahn
André Fisahn
SPSean Palecek
Sean Palecek

19 July 2022 in Cell Reports
Verified
Journal Article
Open access
YCYun Chang
Yun Chang
RSRamizah Syahirah
Ramizah Syahirah
XWXuepeng Wang
Xuepeng Wang
GJGyuhyung Jin
Gyuhyung Jin
STSandra Torregrosa-Allen
Sandra Torregrosa-Allen
XBXiaoping Bao
Xiaoping Bao
Neutrophils, the most abundant white blood cells in circulation, are closely related to cancer development and progression. Healthy primary neutrophils present potent cytotoxicity against various cancer cell lines through direct contact and via generation of reactive oxygen species. However, due to their short half-life and resistance to genetic modification, neutrophils have not yet been engineered with chimeric antigen receptors (CARs) to enhance their antitumor cytotoxicity for targeted immunotherapy. Here, we genetically engineered human pluripotent stem cells with synthetic CARs and differentiated them into functional neutrophils by implementing a chemically defined platform. The resulting CAR neutrophils present superior and specific cytotoxicity against tumor cells both in vitro and in vivo. Collectively, we established a robust platform for massive production of CAR neutrophils, paving the way to myeloid cell-based therapeutic strategies that would boost current cancer-treatment approaches.